

Corporate Fact Sheet



As of December 31, 2011

OFFICES

4 Maguire Road
Lexington, MA 02421
e-mail: info@curis.com
URL: www.curis.com
Phone: 617-503-6500
Fax: 617-503-6501

BUSINESS

Drug Development with a small molecule cancer focus

FOUNDED

2000

OWNERSHIP

Publicly traded on NASDAQ Global Market ("CRIS")

SHARES

77.1 million basic shares outstanding
89.8 fully diluted shares outstanding

EMPLOYEES

Approximately 35

COLLABORATIONS

(1) Genentech: Hedgehog pathway inhibitor (Cancer)
(2) Debiopharm: Hsp90 (Cancer)

TRANSFER AGENT

BNY Mellon Shareowner Services
P.O. Box 358015
Pittsburgh, PA 15252-8015
URL: www.bnymellon.com/shareowner/isd
Phone: 877-810-2248

Please see Curis' Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings that we periodically make with the Securities & Exchange Commission for additional information on the company and its status based on filing date.

MANAGEMENT TEAM

Daniel R. Passeri, President and
Chief Executive Officer

Michael P. Gray, Chief Financial Officer and
Chief Operating Officer

Mark W. Noel, Vice President, Technology Management and
Intellectual Property

Maurizio Voi, M.D., Chief Medical Officer and Chief
Development Officer

BOARD OF DIRECTORS

James R. McNab, Jr. - Chairman of the Board

Susan B. Bayh

Martyn D. Greenacre

Kenneth I Kaitin, Ph.D.

Robert E. Martell, M.D., Ph.D.

Daniel R. Passeri

Marc Rubin, M.D.

James R. Tobin

Michael Gray
COO and CFO

Curis, Inc.
4 Maguire Road
Lexington, MA 02421

Tel. 617.503.6500
Fax. 617.503.6501
www.curis.com